In 2011, the World Health Organisation (WHO) via the International Agency for Research on Cancer (IARC) classified RFR as Group 2B ‘Possibly carcinogenic to humans’1. Glioblastoma Multiforme (GBM), an associated rapidly progressive fatal brain cancer and acoustic neuroma, satisfy the Hill criteria for causality from RFR exposure based on human epidemiological studies2. Human epidemiological evidence continued to accumulate3–4. In 2018 the largest animal study so far, published, from the highly credible US National Toxicology Program (NTP)5–6, declared the evidence for carcinogenesis ‘clear’, putting pressure on IARC to reassess urgently and elevate RFR to Group 1 ‘Known Human Carcinogen’7–8. Furthermore, the large-scale Ramazzini Institute study9 which used far field radiation designed to emulate base station type radiation was published shortly afterwards and independently confirmed promotion of carcinogenesis in cells of glial derivation. Legal authorities continue to validate the causal link between RFR and tumours10. The incidence of these kinds of brain tumours are rising in the UK11, Netherlands12, Australia13 and USA14–15.